Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
NCT00099333 on ClinicalTrials.gov · last registry update 2015-02-23
A small phase 2 — 49 participants, against a typical 110. The sponsor logged completion for August 2005. Primary outcome, as filed: Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 49
- Started
- 2004-02
- Primary completion
- 2005-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.